Drug Trial Radar · NCT00751621
Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)
Last checked: Nov 19, 2026Latest source record: Apr 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Aug 2008
Primary completion
Dec 2011
Study completion Dec 2011
Sponsor
- Lead sponsor
- CSL BehringIndustry
- Sponsor type
- Industry
- First posted
- Sep 12, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a continuation of the study ZLB06\_001CR with the objective of assessing efficacy, tolerability, safety of IgPro, as well as long-term health-related quality of life in patients with PID.
Conditions
- Primary Immunodeficiency (PID)
Interventions
IgPro20Biological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Total Serum IgG Trough LevelsTime frame: Up to 42 months
Locations
13 sites in 8 countries. Site status is shown where the registry gives one.
Study Site
Paris, France
Study Site
Berlin, Germany
Study Site
Freiburg im Breisgau, Germany
Study Site
Leipzig, Germany
Study Site
Mainz, Germany
Study Site
Warsaw, Poland
Study Site
Cluj-Napoca, Romania
Study Site
Timișoara, Romania
Study Site
Barcelona, Spain
Study Site
Seville, Spain
Study Site
Gothenburg, Sweden
Study Site
Bern, Switzerland
Study Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.